Cargando…

Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer

Although ovarian cancer is a rare disease, it constitutes the fifth leading cause of cancer death among women. It is of major importance to develop new therapeutic strategies to improve survival. Combining P8-D6, a novel dual topoisomerase inhibitor with exceptional anti-tumoral properties in ovaria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flörkemeier, Inken, Hillmann, Julia S., Weimer, Jörg P., Hildebrandt, Jonas, Hedemann, Nina, Rogmans, Christoph, Dempfle, Astrid, Arnold, Norbert, Clement, Bernd, Bauerschlag, Dirk O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505822/ https://www.ncbi.nlm.nih.gov/pubmed/36142413 http://dx.doi.org/10.3390/ijms231810503

Ejemplares similares

High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer
por: Flörkemeier, Inken, et al.
Publicado: (2021)

Nectin-4 as Blood-Based Biomarker Enables Detection of Early Ovarian Cancer Stages
por: Rogmans, Christoph, et al.
Publicado: (2022)

Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer
por: Flörkemeier, Inken, et al.
Publicado: (2021)

ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids
por: Hedemann, Nina, et al.
Publicado: (2021)

ADAM17—A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer
por: Rogmans, Christoph, et al.
Publicado: (2021)

Fluorescence in situ hybridization test for detection of endometrial carcinoma cells by non‐invasive vaginal swab
por: Weimer, Jörg, et al.
Publicado: (2023)

Chemotherapy‐induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer
por: Hugendieck, Gerrit, et al.
Publicado: (2023)

ADAM17 inhibition enhances platinum efficiency in ovarian cancer
por: Hedemann, Nina, et al.
Publicado: (2018)

The Aza-Analogous Benzo[c]phenanthridine P8-D6 Acts as a Dual Topoisomerase I and II Poison, thus Exhibiting Potent Genotoxic Properties
por: Aichinger, Georg, et al.
Publicado: (2020)

Bispecific antibodies enhance tumor‐infiltrating T cell cytotoxicity against autologous HER‐2‐expressing high‐grade ovarian tumors
por: Oberg, Hans‐Heinrich, et al.
Publicado: (2019)

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase
por: Znojek, P, et al.
Publicado: (2014)

PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage
por: Das, Benu Brata, et al.
Publicado: (2014)

Topoisomerase IIα in Chromosome Instability and Personalized Cancer Therapy
por: Chen, Tao, et al.
Publicado: (2014)

Dual function of HPF1 in the modulation of PARP1 and PARP2 activities
por: Kurgina, Tatyana A., et al.
Publicado: (2021)

Tetraspanin 8 Subfamily Members Regulate Substrate-Specificity of a Disintegrin and Metalloprotease 17
por: Müller, Miryam, et al.
Publicado: (2022)

Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules
por: Matsuno, Yusuke, et al.
Publicado: (2018)

Aberrant Topoisomerase-1-DNA Lesions are Pathogenic in Neurodegenerative Genome Instability Syndromes
por: Katyal, Sachin, et al.
Publicado: (2014)

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2020)

Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53
por: Baumann, Cindy, et al.
Publicado: (2006)

Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer
por: Boerner, Julie L., et al.
Publicado: (2015)

PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin
por: Mouly, Laetitia, et al.
Publicado: (2018)

Deletion of Topoisomerase 1 in excitatory neurons causes genomic instability and early onset neurodegeneration
por: Fragola, Giulia, et al.
Publicado: (2020)

Topoisomerase 1-dependent R-loop deficiency drives accelerated replication and genomic instability
por: Sarni, Dan, et al.
Publicado: (2022)

PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells
por: Ito, Shuhei, et al.
Publicado: (2016)

Chromatin remodeller SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated genomic instability
por: Husain, Afzal, et al.
Publicado: (2016)

Cleavage-defective Topoisomerase I mutants sharply increase G-quadruplex-associated genomic instability
por: Berroyer, Alexandra, et al.
Publicado: (2022)

Dual Inhibitors of PARPs and ROCKs
por: Antolín, Albert A., et al.
Publicado: (2018)

Dual Inhibitors Against Topoisomerases and Histone Deacetylases
por: Seo, Young Ho
Publicado: (2015)

Mycoplasma fermentans Inhibits the Activity of Cellular DNA Topoisomerase I by Activation of PARP1 and Alters the Efficacy of Its Anti-Cancer Inhibitor
por: Afriat, Reuven, et al.
Publicado: (2013)

Topoisomerase IV can functionally replace all type 1A topoisomerases in Bacillus subtilis
por: Reuß, Daniel R, et al.
Publicado: (2019)

Characterization of a pathway of genomic instability induced by R-loops and its regulation by topoisomerases in E. coli
por: Brochu, Julien, et al.
Publicado: (2023)

TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy
por: Alagoz, Meryem, et al.
Publicado: (2014)

PARP14 is a PARP with both ADP-ribosyl transferase and hydrolase activities
por: Đukić, Nina, et al.
Publicado: (2023)

MACROD2 deletions cause impaired PARP1 activity and chromosome instability in colorectal cancer
por: Sakthianandeswaren, Anuratha, et al.
Publicado: (2018)

PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers
por: Sokol, Ethan S., et al.
Publicado: (2022)

ADP-ribosyltransferases Parp1 and Parp7 safeguard pluripotency of ES cells
por: Roper, Stephen J., et al.
Publicado: (2014)

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro
por: Bowman, K J, et al.
Publicado: (2001)

PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells()
por: Węsierska-Gądek, Józefa, et al.
Publicado: (2012)

PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models
por: Guillot, Clément, et al.
Publicado: (2014)

ADP-ribosyltransferase PARP11 suppresses Zika virus in synergy with PARP12
por: Li, Lili, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lvfbhnj9cheh65mumn58rg3gbu